These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 22101903)

  • 1. Novel options for the treatment of castration-resistant prostate cancer.
    Ohlmann CH; Merseburger AS; Suttmann H; Schilling D; Trojan L; Kempkensteffen C; Corvin S; Mathers MJ; Bastian PJ
    World J Urol; 2012 Aug; 30(4):495-503. PubMed ID: 22101903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients.
    Attard G; de Bono JS
    Clin Cancer Res; 2011 Jun; 17(12):3867-75. PubMed ID: 21680542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New therapeutics to treat castrate-resistant prostate cancer.
    Acar O; Esen T; Lack NA
    ScientificWorldJournal; 2013; 2013():379641. PubMed ID: 23781155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in second-line treatment of castration-resistant prostate cancer.
    Ong M; Winquist E
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):199-205. PubMed ID: 21734586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Castration-resistant prostate cancer: current and emerging treatment strategies.
    Di Lorenzo G; Buonerba C; Autorino R; De Placido S; Sternberg CN
    Drugs; 2010 May; 70(8):983-1000. PubMed ID: 20481655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New agents for prostate cancer.
    Agarwal N; Di Lorenzo G; Sonpavde G; Bellmunt J
    Ann Oncol; 2014 Sep; 25(9):1700-1709. PubMed ID: 24658665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and emerging treatments in the management of castration-resistant prostate cancer.
    Shapiro D; Tareen B
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):951-64. PubMed ID: 22845410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting continued androgen receptor signaling in prostate cancer.
    Massard C; Fizazi K
    Clin Cancer Res; 2011 Jun; 17(12):3876-83. PubMed ID: 21680543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.
    Antonarakis ES; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):192-205. PubMed ID: 21577234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDV3100 for the treatment of prostate cancer.
    Mukherji D; Pezaro CJ; De-Bono JS
    Expert Opin Investig Drugs; 2012 Feb; 21(2):227-33. PubMed ID: 22229405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of metastatic castration-resistant prostate cancer following docetaxel].
    Beuzeboc P; Ropert S; Goldwasser F; Zerbib M
    Bull Cancer; 2012 Jul; 99 Suppl 1():S66-72. PubMed ID: 22516457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant.
    Altavilla A; Iacovelli R; Procopio G; Alesini D; Risi E; Campennì GM; Palazzo A; Cortesi E
    Cancer Biol Ther; 2012 Sep; 13(11):1001-8. PubMed ID: 22825325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of patients with castration-resistant disease.
    Pezaro C; Omlin A; Lorente D; de Bono J
    Hematol Oncol Clin North Am; 2013 Dec; 27(6):1243-60, ix. PubMed ID: 24188261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
    Rehman Y; Rosenberg JE
    Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
    Payne H; Bahl A; Mason M; Troup J; De Bono J
    BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
    Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging treatment options for patients with castration-resistant prostate cancer.
    George D; Moul JW
    Prostate; 2012 Feb; 72(3):338-49. PubMed ID: 21748753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR; Hussain MH
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.